Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 10% world market = $100M + two digits loyalty

<< Previous

Bullboard Posts

Next >>

Post by Actuarialon Feb 09, 2021 9:39am

176 Views

Post# 32511301

10% world market = $100M + two digits loyalty

ATB-346 alone worth over $1B cash + two digits loyalty = a few Billions
ATE = 346+358+340+other in developments = $10B - $20B
$500CAD per share is not a dream
GLTA longs!

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December